key: cord-0765493-j26q6o0u
authors: Strassmair, Michael; Stangl, Manfred
title: Alpha-1 Antitrypsin Deficiency and COVID-19 Infection
date: 2020-10-22
journal: Arch Bronconeumol
DOI: 10.1016/j.arbres.2020.10.009
sha: 25d36d42ce3a6c0db173896e98641961edb62dd3
doc_id: 765493
cord_uid: j26q6o0u

nan

Besides their ability to act as immunomodulators, mesenchymal stem cells have the property to accumulate almost exclusively in lung tissue after application. First clinical results with single applications of stem cells at COVID-19 patients showed an unproblematic application without significant side effects. An increase of lymphocytes as well as T-cells could be achieved within a period of two days. In addition, a significant decrease in serum levels of IL-6, TNFalpha and CRP was found. Parallel to the normalization of the laboratory parameters an improvement of the clinical symptoms as well as the radiological findings was observed (6) .

Combining both principles in a genetically engineered stem cell expressing Alpha-1-Antitrypsin provides an effective therapy for severely ill patients.

In order to achieve high levels of AAT in the affected tissues (lung), MSCs are a suitable vehicle due to their "homing potential". Besides their modulating effect on immunological processes, mesenchymal stem cells show the ability to accumulate in diseased tissue. A modern therapy concept with a genetically modified stem cell expressing alpha-1 antitrypsin seems conclusive and reasonable.

Geographical Overlap Between Alpha-1 Antitrypsin Deficiency and COVID-19 Infection in Italy: Casual or Causal? [Superposición geográfica entre la deficiencia de alfa-1 antitripsina y la infección por COVID-19 en Italia

Characterization of the Inflammatory Response to Severe COVID-19 Illness

Alpha-1 antitrypsin inhibits SARS-CoV-2 infection

Proteasemediated enhancement of severe acute respiratory syndrome coronavirus infection

Lysosomal Proteases Are a Determinant of Coronavirus Tropism

Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia